Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

MUHC researchers link asthma drugs and cataracts in seniors

02.06.2006

Researchers from the MUHC have found that elderly patients with chronic obstructive pulmonary disease (COPD) and asthma who take medication to prevent their attacks face an increased risk of developing cataracts. Their findings, which looked at a large group of Quebecers, are released today in the June issue of the European Respiratory Journal.

"We found that people over the age of 65 who take a cortisone-like medication called inhaled corticosteroids (ICS) to lower their risk of asthma or COPD attacks are actually raising their risk of developing cataracts," says MUHC epidemiologist Dr. Samy Suissa and senior author of the study. "This important information to physicians and patients will help in the management of patients using these drugs"

The researchers looked at 14 years of diagnostic and prescription information from a provincial health database, studying more than 100,000 patients with asthma or COPD with the average age of 78, over 10,000 of whom were subsequently diagnosed with severe cataracts.

The team found a 24 percent increase in the risk of developing a severe cataract for those subjects taking a typical daily dose of ICS. Even at half the daily dose, the researchers found a small increase in the risk of cataracts, a condition that clouds or darkens the lens of the eye and, when left untreated, can permanently blur vision.

The findings lead the researchers to put forth a word of warning: "We recommend that elderly asthma sufferers keep using these very effective medications, but make efforts to reduce the dose of ICS as much as possible," said Dr. Suissa, who is also a professor in McGill University’s Department of Epidemiology and Biostatistics. He suggests that if seniors do have to take ICS, they use the medication in combination with other drugs that open up the bronchial tubes such as long-acting bronchodilators or anti-leukotrienes. For patients with COPD, however, the message is clear: given the limited efficacy of ICS in COPD, we recommend avoiding their use altogether.

The study was funded by the Fonds de la Recherche en Santé du Québec. Samy Suissa is the recipient of a Distinguished Investigator award from the Canadian Institutes of Health Research.

The Research Institute of the McGill University Health Centre (RI MUHC) is a world-renowned biomedical and health care hospital research centre. Located in Montreal, Quebec, the institute is the research arm of the MUHC, a university health centre affiliated with the Faculty of Medicine at McGill University. The institute supports over 500 researchers, nearly 1,000 graduate and postdoctoral students, and operates more than 300 laboratories devoted to a broad spectrum of fundamental and clinical research. The Research Institute operates at the forefront of knowledge, innovation and technology and is inextricably linked to the clinical programs of the MUHC, ensuring that patients benefit directly from the latest research-based knowledge. For further details visit the Research Institute website.

The McGill University Health Centre (MUHC) is a comprehensive academic health institution with an international reputation for excellence in clinical programs, research and teaching. The MUHC is a merger of five teaching hospitals affiliated with the Faculty of Medicine at McGill University--the Montreal Children’s, Montreal General, Royal Victoria, and Montreal Neurological Hospitals, as well as the Montreal Chest Institute. Building on the tradition of medical leadership of the founding hospitals, the goal of the MUHC is to provide patient care based on the most advanced knowledge in the health care field, and to contribute to the development of new knowledge.

Ian Popple | MUHC
Further information:
http://www.muhc.ca

More articles from Health and Medicine:

nachricht The end of pneumonia? New vaccine offers hope
23.10.2017 | University at Buffalo

nachricht Scientists track ovarian cancers to site of origin: Fallopian tubes
23.10.2017 | Johns Hopkins Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

The end of pneumonia? New vaccine offers hope

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>